Blog

ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

– ImmuneID, Inc. has raised $50m in Series A financing. – The round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management. – All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others. – Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.